Brijesh Kumar Srivastava, R. Soni, Jayendra Z. Patel, Mukul R Jain, P. Patel
{"title":"Oxazolidinone Antibacterials and Our Experience","authors":"Brijesh Kumar Srivastava, R. Soni, Jayendra Z. Patel, Mukul R Jain, P. Patel","doi":"10.2174/187152108785908820","DOIUrl":null,"url":null,"abstract":"The Oxazolidinones are a promising novel chemical synthetic class of antibiotics identified in the last two dec- ades and have been subjected to intensive discovery efforts. They possess impressive antibacterial activity against Gram- positive pathogens. Oxazolidinones act through a unique mechanism of inhibitory bacterial protein biosynthesis. Linezolid (Zyvox TM ) has been the only drug of oxazolidinone class to reach the market after USFDA approval. Here we review our efforts directed to the discovery of novel oxazolidinone antibacterials evolved through structure-activity relationship (SAR) and an overview of contemporary on going efforts.","PeriodicalId":89320,"journal":{"name":"Anti-infective agents in medicinal chemistry","volume":"121 1","pages":"258-280"},"PeriodicalIF":0.0000,"publicationDate":"2008-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/187152108785908820","citationCount":"16","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anti-infective agents in medicinal chemistry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/187152108785908820","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 16
Abstract
The Oxazolidinones are a promising novel chemical synthetic class of antibiotics identified in the last two dec- ades and have been subjected to intensive discovery efforts. They possess impressive antibacterial activity against Gram- positive pathogens. Oxazolidinones act through a unique mechanism of inhibitory bacterial protein biosynthesis. Linezolid (Zyvox TM ) has been the only drug of oxazolidinone class to reach the market after USFDA approval. Here we review our efforts directed to the discovery of novel oxazolidinone antibacterials evolved through structure-activity relationship (SAR) and an overview of contemporary on going efforts.